The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.
Four reasons for investors to buy biotechnology stocks now: Beaten-down biotechnology stocks have been so cheap for so long, rattled investors pray every day that a big drug company with firepower will swoop in and buy one to spark interest in the industry.
Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-The Medicines Company. #MDCO
Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his two biotech stock picks for 2015 that have risen 33% and 41%. #NVAX #MDCO
This recommended biotech stock (Alkermes) has delivered the goods with outstanding positive top line data in a treatment for depressions, explains leading biotech analyst John McCamant, editor of The Medical technology Stock Letter.
The move away from opiods is gaining momentum, explains biotech sector John McCamant, editor The Medical Technology Stock Letter.
Jay Silverman, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his top pick for 2016-Anthera Pharmaceuticals. #ANTH
Recent volatility has created an environment for biotech stocks in which company fundamentals are mispriced relative to their stock prices, according to John McCamant. Here, the editor of The Medical Technology Stock Letter discusses the current state of the biotech market and highlights a trio of well-positioned stocks currently being undervalued by the market.
John McCamant of BioInvest’s Medical Technology Stock Letter, updates us on the state of the sector, the primary catalysts he sees over the rest of the year, and a trio of favorite stocks poised for potentially exciting results.
Dozens of biotech companies are ‘free’ for investors’ taking
John McCamant, of BioInvest’s Medical Technology Stock Letter, talks with The Money Show about his biotech stock picks for 2015, one of which (FPRX) that has risen 50%. #FPRX #PCYC
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.
